Prostate Cancer News Today: “Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality”

“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...
Read More

ABS 2017 Insights and Takeaways

A thorough discussion on value, detailed brachytherapy delivery techniques and ways clinicians can reach new patients: Isoray's ABS 2017 insights and takeaways including Dr. Steven Frank, Dr. Alex Hsi and Harvard Business School Professor Emeritus Dr. Robert Kaplan.
Read More

IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017

IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will be presenting at the...
Read More

Still Going Strong After 15,000 Cases: Chicago Prostate Cancer Center Focuses on What is Best for the Patient

Brian J. Moran MD, Medical Director of Chicago Prostate Cancer Center, has been performing brachytherapy procedures to treat prostate cancer since 1990, with over 15,000 brachytherapy treatments to date. In that 27+ years, he has placed a high value in the...
Read More

Did Beau Biden’s Battle with Brain Cancer Change the Course of History?

Change in healthcare can be agonizingly slow. The scientific rigors and huge financial investments needed to bring novel life saving therapies help ensure physicians do no harm. However, in the grinding shift from fee for service to value-based care it is high time to...
Read More

Recent News

IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131”

At Median 5.5 Years Post-Treatment, Return to Baseline is Sustained RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...

ABS 2017 Insights and Takeaways

A thorough discussion on value, detailed brachytherapy delivery techniques and ways clinicians can reach new patients: Isoray’s ABS 2017 insights and takeaways including Dr. Steven Frank, Dr. Alex Hsi and Harvard Business School Professor Emeritus Dr. Robert Kaplan.

Isoray Patients Tell Their Stories

Herbert L   During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests run at the Chicago Prostate Cancer Center with Dr. Brian Moran, Herbert learned about his options for treatment, one of...

Cs-131 is a favorable isotope for use across a wide range of tumors and its dose distribution properties facilitate easy calculation and use in the clinic. Dr. Voichita Bar-Ad

Thomas Jefferson University Hospital

Find A Cesium Pioneer Near You

Doctors going above and beyond against the fight with cancer. Learn More

All News

IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131”

At Median 5.5 Years Post-Treatment, Return to Baseline is Sustained RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...

ABS 2017 Insights and Takeaways

A thorough discussion on value, detailed brachytherapy delivery techniques and ways clinicians can reach new patients: Isoray’s ABS 2017 insights and takeaways including Dr. Steven Frank, Dr. Alex Hsi and Harvard Business School Professor Emeritus Dr. Robert Kaplan.

Isoray Patients Tell Their Stories

Herbert L   During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests run at the Chicago Prostate Cancer Center with Dr. Brian Moran, Herbert learned about his options for treatment, one of...

Bringing Compassion and Hope to Cancer Patients

The following article originally appeared in the Winter/Spring 2017 MicroCap Review Magazine. A small company in Richland, WA is dedicated to making a difference in the lives of patients diagnosed with different forms of cancer. Isoray Medical, Inc. [NYSE MKT:ISR] has...

Women’s Cancer and Cesium-131 Treatments

Topic of Two Presentations at the 2016 Annual Meeting of the American Brachytherapy Society and World Congress of Brachytherapy RICHLAND, Wash., July 6, 2016 /PRNewswire/ — IsoRay Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy...